104 results about "Kallikrein" patented technology

The invention belongs to the technical field of daily chemistry, and provides a triple compound acid composition with skin brightening and acne removing effects, a product and application of the triple compound acid composition and the product, the triple compound acid composition comprises mandelic acid, salicylic acid and succinic acid, and the mass ratio of the mandelic acid to the salicylic acid to the succinic acid is (3-6): (1-2): (1-2). The invention further provides a product containing the composition and application of the product. The composition provided by the invention is synergistically used, has a synergistic effect in the aspect of exfoliating, especially in the aspect of improving the activity of kallikrein 5 (KLK5), not only has the effects of biological skin glowing and exfoliating, but also can efficiently down-regulate the expression of I-type 5alpha-reductase genes, so that the synthesis of sebum is inhibited, and an oil control effect is achieved; in addition, the composition provided by the invention has the effects of brightening, inhibiting bacteria and resisting inflammation, has low sensitization, can be used for removing acnes, takes effect quickly and does not relapse.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS; diagnosing that the subject in undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject; and administering a therapeutically effective amount of treatment for RRMS to the subject.

The invention belongs to the technical field of daily-use chemistry, and particularly relates to a keratin regulating composition containing mandelic acid and having skin smoothing and brightening effects and application of the keratin regulating composition. The composition provided by the invention comprises mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate. According to the application, mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate are compounded, so that the activity of KLK family proteases, especially kallikrein 5 (KLK5), can be obviously promoted, the decomposition of desmosome between keratinocytes is promoted, epidermal cells lose cohesion and finally naturally fall off, and the effect of promoting the activity of KLK family proteases is achieved. The cutin exfoliation promoting effect is achieved, so that the problems of skin darkness, roughness, pore blockage, acne and the like are solved, the glossiness and fineness of the skin are improved, and healthy and bright skin is achieved.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The invention discloses a polypeptide composition for promoting skin desquamation and a preparation method and application thereof, the polypeptide composition comprises polypeptides and a polyol preservative, the polypeptides comprise a first polypeptide, a second polypeptide and a third polypeptide, and the first polypeptide is acetyl tetrapeptide-2; the second polypeptide comprises one or more of hyaluronic acid polypeptide, red scorpion toxin and palmitoyl tripeptide-5; and the third polypeptide is prepared from one or more of acetyl octapeptide-3, palmitoyl dipeptide-7, acetyl tetrapeptide-9 and acetyl tetrapeptide-11. The polypeptide composition can significantly up-regulate the gene expression of kallikrein through a synergistic effect and promote old cutin exfoliation; meanwhile, gene expression of metalloproteinase is inhibited, and light aging is delayed. The polypeptide composition disclosed by the invention can be prepared into various cosmetics and has multiple effects of promoting skin desquamation, resisting wrinkles and repairing barriers.

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more compounds of Formula I compounds, and methods for using the compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

The present invention provides compounds of Formula (I):or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and / or inflammatory disorders using the same.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.

The application belongs to the technical field of cosmetics and skin external preparation, and discloses a retinoid, a preparation method and application thereof. The compound is formed by covalently coupling a Schiff base or a kinin releasing enzyme cleavable peptide bond (L) and a free L-amino acid, a di- to hexapeptide or a C6-C22 fatty acid ester (P) of the retinol parent (R), and the structural general formula is R-L-P. The compound has a 12-week stability rate of ≥80% in a 25℃ aqueous preparation, is recognized by a keratin layer carboxylic acid esterase and a kinin releasing enzyme KLK-5 / KLK-7 after being applied to the skin, is subjected to enzymatic cutting in a skin acidic cuticle (pH 4.5-5.5) microenvironment, and releases free retinol at a fixed point. Compared with retinol palmitate, the in-situ release efficiency of the compound of the application is increased by 2.5-4.5 times, while the risk of systemic absorption is significantly reduced, and the incidence of sensitive skin irritation is ≤6.7%.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and methods of using such proteins are described.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

To provide chimeric antigen receptors (CARs) that specifically bind to a human Kallikrein-2 (hK2), and immunoresponsive cells comprising such CARs, for the treatment of cancer.SOLUTION: Provided is a chimeric antigen receptor (CAR) comprising: (a) an extracellular domain that specifically binds to a human Kallikrein-2 (hK2) antigen, (b) a transmembrane domain, and (c) an intracellular signaling domain optionally comprising at least one costimulatory domain.SELECTED DRAWING: Figure 1A

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a cyclic polypeptide CycSD6 of a targeted contact kinin system and application of the cyclic polypeptide CycSD6. The cyclic polypeptide CycloSD6 provided by the invention comprises an amino acid sequence as shown in SEQ ID NO: 1; the head and the tail of the amino acid sequence as shown in SEQ ID NO: 1 form a ring through an amido bond. The head and tail amido bonds of the amino acid sequence as shown in SEQ ID NO: 1 are cyclized, the plasma stability of the straight-chain polypeptide as shown in SEQ ID NO: 1 can be improved, and compared with the straight-chain polypeptide, the cyclized cyclic polypeptide has the advantages that the inhibitory activity on plasma kallikrein and blood coagulation factor XIIa is further improved, the plasma recalcification time and the partial thromboplastin activating time can be prolonged, and the blood coagulation factor XIIa can be inhibited. The compound has good anti-thrombus and cerebral apoplexy activity effects, does not cause hemolysis and bleeding risks, and is low in cytotoxicity and high in safety.

The present invention discloses a recombinant humanized filaggrin and its uses. The recombinant humanized filaggrin contains a humanized LEKTI protein fragment, and the humanized LEKTI protein fragment contains the humanized Kazal motif protein sequence shown in SEQ ID No.2; it also contains a humanized FLG protein fragment, and the humanized FLG protein fragment is linked to the humanized LEKTI protein fragment through a linker containing a furin cleavage site. After cleavage by interstitial furin protease, the two protein fragments perform their respective functions. The recombinant humanized filaggrin of the present invention has the prospect of being developed into a drug, a cosmetic or a medical device for treating diseases that can be treated or alleviated by supplementing FLG and / or inhibiting kallikrein KLK5. Diseases that can be treated or alleviated by supplementing FLG and / or inhibiting KLK5 include atopic dermatitis, Netherton syndrome and tumors with high expression of KLKs.

Disclosed are tricyclic heteroaromatic compounds of formulae (I) and (II), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity activity, such as Netherton Syndrome. Formulae (I) and (II)

The present application relates to the preparation of new physiological and pharmaceutically active molecules, and belongs to the field of pharmaceutical synthesis chemistry, and relates to the design and preparation of a class of molecules capable of inhibiting the activity of human kallikrein. Firstly, fluoroacrylic acid and alcohol compounds are used as raw materials to obtain a class of fluoroallyl alcohol compounds; then the fluoroallyl alcohol is condensed with carboxylic acid compounds to obtain fluoroallyl carboxylic acid ester compounds with general formula (I) capable of inhibiting the activity of human kallikrein. The compounds are considered to be useful for treating diabetic complications, eye diseases and edema-related diseases. In addition, they have potential applications in the diagnosis and treatment of some cancers.

To provide a plasma kallikrein binding protein and use method thereof.SOLUTION: A plasma kallikrein binding protein binds to or competes for binding with a protein (for example, epi-Kal2) and / or a same epitope as a low molecule (AEBSF, for example), and does not bind to a pre-plasma kallikrein. The plasma kallikrein binding protein may have a full length (for example, IgG, IgM, IgA, IgD and IgE) or may include only an antigen binding fragment (for example, Fab, F(ab')2 or scFv fragment). The binding protein may include two heavy chain immunoglobulins and two light chain immunoglobulins or may have a single chain antibody.SELECTED DRAWING: None